Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. - Wikidata - wikimedia - TriplyDB

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

http://www.wikidata.org/entity/Q37864183

about

Paired measurements of paraoxonase 1 and serum amyloid A as useful disease markers Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins Dialysis Modalities and HDL Composition and Function Paraoxonase 1 in chronic kidney failure Ischemia-modified albumin (IMA): could it be useful to predict perinatal asphyxia?Evaluation of the Relationship Between Microalbuminuria and Urine Ischemia-Modified Albumin Levels in Patients with Diabetic Nephropathy.Serum ischemia modified albumin is a possible new marker of oxidative stress in phenylketonuria.

P2860

Q27006749-EEAAB6BD-B6FF-4C5C-A5FF-F49525E59019 Q28074264-D039AEED-A477-4BA7-AB0D-2E1E20583BB8 Q36003077-D6A45217-E112-4BC3-8D95-C6FAD71D94BF Q38004498-3C6BDE02-C3EA-4DC6-BE6C-E904A12CF1B5 Q38014107-FECCFF5B-9853-491A-96A0-CD69F1104A6D Q39328364-AAAD5279-1D66-4F67-B7C2-F4FF82FC6DE4 Q47899947-9FC204AF-99C5-4F63-A123-ADB30ED2042A

P2860

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

http://www.wikidata.org/entity/Q37864183

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

@en

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

@nl

type

label

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

@en

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

@nl

prefLabel

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

@en

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

@nl

P1433

Q37864183-B9332521-A24C-4302-B79D-719240199C3A

P1476

Q37864183-D00CD5FB-1473-4A2E-AC3E-0CCF46B157FF

P2093

Q37864183-8176DE7D-EFC4-472E-9E2D-22333393EEAD

Q37864183-9C63A71A-81CF-4077-A7B8-5B74A9A991C1

Q37864183-CCEA66FB-7C82-49EB-BE01-CA723E575293

P2860

Q37864183-041BF010-CC16-4528-A1E6-EEB6F72BF2B7

Q37864183-18035870-5C4D-4D13-A4E2-643EDDACA172

Q37864183-19776F5A-AEAA-4BA6-8B74-B4B18AD23425

Q37864183-1D7882FF-4B9A-4066-A1F2-8D612F8F9EC3

Q37864183-4DC4D10E-E9AF-48B7-BBD5-F677BDF0A5CD

Q37864183-51D7633D-2D04-4C5E-97B2-99ECBF3CAB48

Q37864183-599EF0A2-BE85-46ED-82F3-6F6501393FE4

Q37864183-5A341F6E-1587-401E-A1A8-3F4F0DD2F9D0

Q37864183-6536A017-2D8C-4873-8ECD-714E3DB46AD2

Q37864183-653EEBC6-A20D-4883-84E6-2C238BDF10D5

P2888

Q37864183-6646044A-74B4-4B88-86C0-146B0B59D17B

P304

Q37864183-9DD7821B-95ED-4343-910B-A9E2313B0C3E

P31

Q37864183-716556F4-FC2B-472B-941A-65D578CBCB46

P356

Q37864183-9095B93E-2EBD-4F59-A1A6-0C0EB9B11474

P433

Q37864183-8DE08FD5-A1C9-43F9-B056-F08723DFB569

P478

Q37864183-8812DAA6-DC14-4657-8375-EA2A476128AA

P577

Q37864183-F2BA99E6-0A6F-4FA2-BE0C-712AEADBFE5A

P5875

Q37864183-5099DA50-FBD8-4BCF-B233-89469FB2FCF0

P698

Q37864183-9BEA2EA5-C109-4AB5-BFF5-8D0C88DF05CC

P356

S13105-011-0092-4

P1433

Journal of Physiology and Biochemistry

P1476

Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.

@en

P2093

Alejandro Gugliucci

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Kotani

http://www.w3.org/2001/XMLSchema#string

Satoshi Kimura

http://www.w3.org/2001/XMLSchema#string

P2860

Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences

Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.

Oxidant stress in hemodialysis patients: what are the determining factors?

The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention.

Ischaemia modified albumin in the diagnosis of acute coronary syndromes.

Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report.

Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options.

Cardiovascular problems on hemodialysis: current deficits and potential improvement.

P2888

s13105-011-0092-4

P304

437-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13105-011-0092-4

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51043227

http://www.w3.org/2001/XMLSchema#string

P698

21484479

http://www.w3.org/2001/XMLSchema#string